Clinical Trial Update: AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update announcing AB-3028, a programmable circuit T cell therapy, for metastatic castration-resistant prostate cancer, with Phase 1/2 currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• AB-3028

Snippet

Sponsor: Arsenal Biosciences, Inc. | Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1, Phase 2 | Status: RECRUITING